KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $4.5 billion.

  • Vertex Pharmaceuticals' Total Current Liabilities rose 1264.0% to $4.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 1264.0%. This contributed to the annual value of $3.6 billion for FY2024, which is 48.49% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Total Current Liabilities stood at $4.5 billion, which was up 1264.0% from $4.1 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Total Current Liabilities ranged from a high of $4.5 billion in Q3 2025 and a low of $1.8 billion during Q2 2021
  • Over the past 5 years, Vertex Pharmaceuticals' median Total Current Liabilities value was $3.4 billion (recorded in 2023), while the average stood at $3.1 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Total Current Liabilities plummeted by 447.91% in 2021 and then soared by 3919.26% in 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' Total Current Liabilities (Quarter) stood at $2.1 billion in 2021, then rose by 28.02% to $2.7 billion in 2022, then grew by 29.37% to $3.5 billion in 2023, then rose by 0.48% to $3.6 billion in 2024, then rose by 25.55% to $4.5 billion in 2025.
  • Its Total Current Liabilities was $4.5 billion in Q3 2025, compared to $4.1 billion in Q2 2025 and $3.8 billion in Q1 2025.